ErythroCure

At ErythroCure, we work towards developing new therapeutics to treat congenital and acquired disorders of the blood, blood-borne diseases, and blood cell cancers so that no child, woman, or man need suffer from these conditions

Science

Utilizing fundamental insights into the physiology of red and white blood cells, ErythroCure is developing novel treatments for a variety of blood disorders, blood-borne pathogens, and blood cancers.

Check out our science here

Pipeline

ErythroCure endeavors to translate new treatment options into clinical practice by advancing lab-based discoveries in basic biology through the drug discovery and development pipeline

View our pipeline here

People

We are assembling a world-class team with diverse expertise in blood cell biology, blood-borne pathogens, oncology, and drug development

View our team here

Latest News

August 2021 - Results of Phase 2 anti-malarial clinical trial published

Data from our anti-malarial Phase 2 clinical trial performed in Vietnam were published in the Journal of Experimental Medicine. These promising results show the strategy of inhibiting host erythrocyte kinases can greatly augment the efficacy of current malaria treatments.

Click here to read the full manuscript

ErythroCure appoints Karson Putt as COO and interim CEO

August 2021 - Results of Phase 2 anti-malarial clinical trial published

In November 2020, Karson Putt joined ErythroCure as the new COO and interim CEO

Find out more

New anti-malarial tyrosine kinase inhibitors published

August 2021 - Results of Phase 2 anti-malarial clinical trial published

New anti-malarial tyrosine kinase inhibitors published

Tyrosine kinase inhibitors that halt the progression of malaria was published in the journal PLoS.

Click here to read the full manuscript